Episodi

  • Route 66 SPORE and the Direction of Endometrial Cancer Research

    Route 66 SPORE and the Direction of Endometrial Cancer Research
    Apr 1 2026

    Drs Ursula A. Matulonis and David G. Mutch discuss past and present endometrial cancer research, including the Route 66 SPORE.

    Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep2-2026a10006ic. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

    Route 66 Endometrial Cancer SPORE https://dctd.cancer.gov/research/spores/state/wustl-endometrial

    Final Analysis of RTOG 9708: Adjuvant Postoperative Irradiation Combined With Cisplatin/Paclitaxel Chemotherapy Following Surgery for Patients With High-Risk Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/16545437/

    Pelvic Radiation With Concurrent Chemotherapy Compared With Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer https://pubmed.ncbi.nlm.nih.gov/10202164/

    Surgical-Pathological Findings in Type 1 and 2 Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study on GOG-210 Protocol https://pubmed.ncbi.nlm.nih.gov/28392124/

    GOG Foundation https://www.gog.org/

    The Latest Updates in Translational Science at NRG Oncology (October 2025) https://www.nrgoncology.org/Home/News/Post/the-latest-updates-in-translational-science-at-nrg-oncology-october-2025/

    Adjuvant Chemotherapy Plus Radiation for Locally Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/31189035/

    Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post-Hoc Analysis by Molecular Classification From a Randomised Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/40921169/

    FIGO Staging of Endometrial Cancer: 2023 https://pubmed.ncbi.nlm.nih.gov/37337978/

    Practical Guidance for Assessing and Reporting Lymphovascular Space Invasion (LVSI) in Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/38937066/

    Surgical Pathologic Spread Patterns of Endometrial Cancer. A Gynecologic Oncology Group Study https://pubmed.ncbi.nlm.nih.gov/3652025/

    Integrated Genomic Characterization of Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/23636398/

    AXL Inhibition Improves the Therapeutic Efficacy of Trastuzumab in High-Risk Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/41270342/

    Patient-Derived Xenograft Mouse Models: A High Fidelity Tool for Individualized Medicine https://pubmed.ncbi.nlm.nih.gov/30655732/


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Mostra di più Mostra meno
    23 min
  • The Future of Endometrial Cancer Therapeutics: Phase 3 Trials of ADCs and Beyond

    The Future of Endometrial Cancer Therapeutics: Phase 3 Trials of ADCs and Beyond
    Apr 1 2026
    Drs Ursula Matulonis and Brian Slomovitz discuss phase 3 trials of ADCs in endometrial cancer and what's to come in the field of endometrial cancer therapeutics. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep1-2026a10006ib. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review https://pubmed.ncbi.nlm.nih.gov/40212845/ Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/ Standardized Pathology Report for HER2 Testing in Compliance With 2023 ASCO/CAP Updates and 2023 ESMO Consensus Statements on HER2-Low Breast Cancer https://pubmed.ncbi.nlm.nih.gov/37770765/ Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) https://clinicaltrials.gov/study/NCT07044336 Safety and Efficacy of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), in Combination With Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer https://pubmed.ncbi.nlm.nih.gov/36736157/ First in Human Study of IMGN151 in Recurrent Gynaecological Cancers https://clinicaltrials.gov/study/NCT05527184 DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (DE-01) https://clinicaltrials.gov/study/NCT06989112 Pembrolizumab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: Overall Survival and Exploratory Analyses of the NRG GY018 Phase 3 Randomized Trial https://pubmed.ncbi.nlm.nih.gov/40044930/ The GOG Highlight Reel July 2025 https://www.gog.org/wp-content/uploads/2025/08/GOG-Highlight-Reel-July-2025-Presentation-7.26.25.pdf Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection https://pubmed.ncbi.nlm.nih.gov/38892080/ Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026) https://pubmed.ncbi.nlm.nih.gov/41385758/ A Phase II Study of Frontline Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/Carboplatin/Temsirolimus, or Ixabepilone/Carboplatin/Bevacizumab in Advanced/Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/29804638/ Mutated p53 Portends Improvement in Outcomes When Bevacizumab Is Combined With Chemotherapy in Advanced/Recurrent Endometrial Cancer: An NRG Oncology Study https://pubmed.ncbi.nlm.nih.gov/33541735/ Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer https://clinicaltrials.gov/study/NCT07198074 WEE1 Inhibitor: Clinical Development https://pubmed.ncbi.nlm.nih.gov/34269904/ Palbociclib Plus Letrozole in Estrogen Receptor-Positive Advanced/Recurrent Endometrial Cancer: Double-Blind Placebo-Controlled Randomized Phase II ENGOT-EN3/PALEO Trial https://pubmed.ncbi.nlm.nih.gov/39657575/ GOG3069: Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-Mutated Estrogen Receptor (ER)-Positive Endometrioid Endometrial Cancers https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS5639 TP004/#1561 A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study of Nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer https://www.sciencedirect.com/science/article/pii/S1048891X24163530 Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities https://pubmed.ncbi.nlm.nih.gov/41329840/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Mostra di più Mostra meno
    25 min
  • Can the Use of ADCs in Breast Cancer Teach Us About Resistance Mechanisms and Sequencing in Endometrial Cancer?

    Can the Use of ADCs in Breast Cancer Teach Us About Resistance Mechanisms and Sequencing in Endometrial Cancer?
    Jun 12 2025

    Drs Ursula A. Matulonis and Leif W. Ellisen discuss endometrial cancer and ADCs, including resistance mechanisms, ADC sequencing, what's exciting in the field, and novel payloads.

    Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s2-ep6-2026a10008nk. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

    The Clinical Landscape of Antibody-Drug Conjugates in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/39074933/

    FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

    Mechanisms of Resistance to Antibody-Drug Conjugates https://pubmed.ncbi.nlm.nih.gov/36831621/

    TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients With Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/39745368/

    Single-Cell Analysis Technologies for Cancer Research: From Tumor-Specific Single Cell Discovery to Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/37900181/

    Spatial Transcriptomics for Tumor Heterogeneity Analysis https://pubmed.ncbi.nlm.nih.gov/35899203/

    Exploring Circulating Tumor DNA (CtDNA) and Its Role in Early Detection of Cancer: A Systematic Review https://pmc.ncbi.nlm.nih.gov/articles/PMC10516512/

    Current and Emerging Prognostic Biomarkers in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35530346/

    Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/

    Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients With Breast Cancer https://pubmed.ncbi.nlm.nih.gov/38709212/

    Antibody-Drug Conjugates as Targeted Therapy for Treating Gynecologic Cancers: Update 2025 https://pubmed.ncbi.nlm.nih.gov/39480912/


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Mostra di più Mostra meno
    26 min
  • The Future of Replication Stress and DNA Damage and Repair in Endometrial Cancer

    The Future of Replication Stress and DNA Damage and Repair in Endometrial Cancer
    May 13 2025

    Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer.

    Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s2-ep5-2026a10008nd. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

    Exploiting Replicative Stress in Gynecological Cancers as a Therapeutic Strategy https://pubmed.ncbi.nlm.nih.gov/32571890/

    Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling Into Place https://pubmed.ncbi.nlm.nih.gov/29653955/

    WEE1 Inhibition in Cancer Therapy: Mechanisms, Synergies, Preclinical Insights, and Clinical Trials https://pubmed.ncbi.nlm.nih.gov/40187712/

    Phase 2 Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma https://pubmed.ncbi.nlm.nih.gov/33705205/

    ADAGIO: A Phase 2b, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.TPS5612

    Azenosertib Monotherapy Yields Encouraging Responses in Cyclin E1+ Proc https://www.cancernetwork.com/view/azenosertib-monotherapy-yields-encouraging-responses-in-cyclin-e1-proc

    Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase 3 Duo-E Trial https://pubmed.ncbi.nlm.nih.gov/37864337/

    Homologous Recombination Deficiency: Concepts, Definitions, and Assays https://pubmed.ncbi.nlm.nih.gov/35274707/

    A Replication Stress Biomarker Is Associated With Response to Gemcitabine vs Combined Gemcitabine and ATR Inhibitor Therapy in Ovarian Cancer https://pubmed.ncbi.nlm.nih.gov/34552099/

    Abstract B144: Discovery and Preclinical Evaluation of Novel Oral WEE1 Degraders https://aacrjournals.org/mct/article/22/12_Supplement/B144/730300/Abstract-B144-Discovery-and-preclinical-evaluation


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Mostra di più Mostra meno
    26 min
  • Endometrial Cancer Trends: Immunotherapy Insights and Research Priorities

    Endometrial Cancer Trends: Immunotherapy Insights and Research Priorities
    Apr 10 2025

    Drs Ursula A. Matulonis and Gini Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field.

    Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s2-ep4-2026a10008na. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Cancer Statistics, 2025 https://pubmed.ncbi.nlm.nih.gov/39817679/

    Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype https://pubmed.ncbi.nlm.nih.gov/35511145/

    The Advent of Immune Checkpoint Inhibition for the Treatment of Patients With Primary Advanced or Recurrent dMMR/MSI High Endometrial Cancer in 2025 https://pubmed.ncbi.nlm.nih.gov/39611619/

    Overall Survival in Patients With Endometrial Cancer Treated With Dostarlimab Plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial https://pubmed.ncbi.nlm.nih.gov/38866180/

    Safety and Antitumor Activity of Dostarlimab in Patients With Advanced or Recurrent DNA Mismatch Repair Deficient/Microsatellite Instability-High (dMMR/MSI-H) or Proficient/Stable (MMRp/MSS) Endometrial Cancer: Interim Results From GARNET-A Phase I, Single-Arm Study https://pubmed.ncbi.nlm.nih.gov/35064011/

    A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo) in Her2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma https://www.nrgoncology.org/Clinical-Trials/Protocol/nrg-gy026?filter=nrg-gy026

    A New Vision for Women's Health Research: Transformative Change at the National Institutes of Health https://pubmed.ncbi.nlm.nih.gov/39652697/

    Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/

    Antibody-Drug Conjugates as Targeted Therapy for Treating Gynecologic Cancers: Update 2025 https://pubmed.ncbi.nlm.nih.gov/39480912/

    A Phase II Study of Frontline Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/Carboplatin/Temsirolimus, or Ixabepilone/Carboplatin/Bevacizumab in Advanced/Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/29804638/


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Mostra di più Mostra meno
    23 min
  • Endometrial Cancer: Molecular Classification, Genetics, When to Rebiopsy, and What's New in the Research

    Endometrial Cancer: Molecular Classification, Genetics, When to Rebiopsy, and What's New in the Research
    Mar 12 2025
    Drs Ursula A. Matulonis and Katherine Fuh discuss the molecular classification and genetics of endometrial cancer as well as when to rebiopsy, research updates, and what's to come in the future. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s2-ep3-2026a10008n7. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists https://pubmed.ncbi.nlm.nih.gov/37627129/ Molecular Testing for Endometrial Cancer: An SGO Clinical Practice Statement https://pubmed.ncbi.nlm.nih.gov/36399812/ TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/36232987/ Histopathological Characterization of ProMisE Molecular Groups of Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/31932106/ Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02 https://pubmed.ncbi.nlm.nih.gov/39261417/ Randomized Phase III Trial of Radiation Therapy With or Without Pembrolizumab for Women With High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer (NRG-GY020) https://www.nrgoncology.org/Home/News/Post/randomized-phase-iii-trial-of-radiation-therapy-with-or-without-pembrolizumab-for-women-with-high-intermediate-risk-mismatch-repair-deficient-dmmr-endometrioid-endometrial-cancer-nrg-gy020 Testing Strategies for Lynch Syndrome in People With Endometrial Cancer https://www.medscape.co.uk/viewarticle/testing-strategies-lynch-syndrome-people-endometrial-cancer-2023a10001yb Endometrial Cancer at Recurrence: To Re-sequence or Not to Re-sequence https://pubmed.ncbi.nlm.nih.gov/38841264/ Molecular Profiling of Primary Endometrioid Endometrial Cancer and Matched Lung Metastases: CTNNB1 Mutation as a Potential Driver https://pubmed.ncbi.nlm.nih.gov/38633674/ Route 66 Endometrial Cancer SPORE https://trp.cancer.gov/spores/abstracts/wustl_endometrial.htm Project 2: Inhibiting AXL to Improve Treatment Response in Endometrial Cancer https://trp.cancer.gov/spores/abstracts/wustl_endometrial.htm#h04 AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA5515 Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer https://pubmed.ncbi.nlm.nih.gov/34884986/ GOG Foundation Overview https://www.gog.org/about/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Mostra di più Mostra meno
    26 min
  • Endometrial Cancer Disparities: Improving Black Women's Access to Care and Trials

    Endometrial Cancer Disparities: Improving Black Women's Access to Care and Trials
    Feb 13 2025

    Drs Ursula A. Matulonis and Eloise Chapman-Davis discuss overcoming health disparities in endometrial cancer and increasing clinical trial enrollment of Black women.

    Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s2-ep2-2026a10007uv. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

    Cancer Statistics, 2025 https://pubmed.ncbi.nlm.nih.gov/39817679/

    An Intervention-Based Approach to Achieve Racial Equity in Gynecologic Oncology https://pubmed.ncbi.nlm.nih.gov/37678907/

    Patient Navigation in Cancer Treatment: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/38581470/

    Disparities in the Allocation of Research Funding to Gynecologic Cancers by Funding to Lethality Scores https://pubmed.ncbi.nlm.nih.gov/30404721/

    ECANA https://www.ecanawomen.org/

    Racial Disparities in Diagnostic Evaluation of Uterine Cancer Among Medicaid Beneficiaries https://pubmed.ncbi.nlm.nih.gov/36788453/

    Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35045221/

    MedExplain https://medexplain.org/

    PALS for Health https://www.palsforhealth.org/


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Mostra di più Mostra meno
    27 min
  • Metastatic Endometrial Cancer: Hormonal Therapy Updates and Ways to Target and Treat ER+ Disease

    Metastatic Endometrial Cancer: Hormonal Therapy Updates and Ways to Target and Treat ER+ Disease
    Feb 13 2025
    Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and treat ER+ metastatic endometrial cancer. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s2-ep1-2026a10008n2. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Is the Positivity of Estrogen Receptor or Progesterone Receptor Different Between Type 1 and Type 2 Endometrial Cancer? https://pubmed.ncbi.nlm.nih.gov/27888807/ Immunophenotypic Diversity of Endometrial Adenocarcinomas: Implications for Differential Diagnosis https://pubmed.ncbi.nlm.nih.gov/16648864/ Progesterone: The Ultimate Endometrial Tumor Suppressor https://pubmed.ncbi.nlm.nih.gov/21353793/ Phase 2 Study of Anastrozole in Recurrent Estrogen (ER)/Progesterone (PR) Positive Endometrial Cancer: The PARAGON Trial - ANZGOG 0903 https://pubmed.ncbi.nlm.nih.gov/31130288/ Phase II Study of Fulvestrant in Recurrent/Metastatic Endometrial Carcinoma: A Gynecologic Oncology Group Study https://pubmed.ncbi.nlm.nih.gov/21075433/ Results From a Phase II Study to Assess the Efficacy and Tolerability of Fulvestrant 250 mg/Month as Treatment of Recurrent or Metastatic Endometrial Carcinoma https://ascopubs.org/doi/10.1200/jco.2009.27.15_suppl.5532 Phase II Trial of Alternating Courses of Megestrol Acetate and Tamoxifen in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study https://pubmed.ncbi.nlm.nih.gov/14751131/ Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/25624430/ A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy in Women With Advanced, Persistent or Recurrent Endometrial Carcinoma: A GOG Foundation Study https://pubmed.ncbi.nlm.nih.gov/35063278/ Everolimus, Letrozole, and Metformin in Women With Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study https://pubmed.ncbi.nlm.nih.gov/31628143/ A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36174113/ Elacestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial https://pubmed.ncbi.nlm.nih.gov/35584336/ CDKN2A Cyclin Dependent Kinase Inhibitor 2A [Homo sapiens (human)] https://www.ncbi.nlm.nih.gov/gene/1029 A Phase II Study of Fulvestrant Plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/39561275/ Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, in Recurrent/Advanced ER-Positive Endometrioid Endometrial Cancer: Results From the Phase 1a/1b EMBER Study https://pubmed.ncbi.nlm.nih.gov/39442371 Palbociclib Plus Letrozole in Estrogen Receptor-Positive Advanced/Recurrent Endometrial Cancer: Double-Blind Placebo-Controlled Randomized Phase II ENGOT-EN3/PALEO Trial https://pubmed.ncbi.nlm.nih.gov/39657575/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Mostra di più Mostra meno
    29 min